Comparative Pharmacology
Head-to-head clinical analysis: LO MINASTRIN FE versus LOARGYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO MINASTRIN FE versus LOARGYS.
LO MINASTRIN FE vs LOARGYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
100 mg orally twice daily.
None Documented
None Documented
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive